Henry O. Gosebruch - 14 Sep 2023 Form 3 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role
President & CEO, Director
Signature
/s/ Joshua Pinto, as Attorney-in-Fact for Henry O. Gosebruch
Issuer symbol
NMRA
Transactions as of
14 Sep 2023
Transactions value $
$0
Form type
3
Filing time
14 Sep 2023, 18:58:09 UTC
Previous filing
11 May 2023
Next filing
19 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NMRA Common Stock 382K 14 Sep 2023 Direct F1
holding NMRA Common Stock 127K 14 Sep 2023 See Footnote F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NMRA Stock Option (Right to Buy) 14 Sep 2023 Common Stock 2.04M $6.36 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects a 1-for-7.8463 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement on September 8, 2023.
F2 Shares held by Lu Leng Felicia Chua Descendants 2012 Irrevocable Trust, of which Reporting Person is trustee.
F3 25% of the shares subject to the option vest on the first anniversary measured from July 3, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Remarks:

Exhibit 24 - Power of Attorney